Abstract 370P
Background
Immune checkpoint inhibitors (ICI) have proven efficacy in R/M HNSCC. In LMICs, <5% of patients have access to ICI at approved doses. We assessed the efficacy of low dose ICI in locally advanced/inoperable HNSCC.
Methods
We conducted retrospective analysis of patients with locally advanced/inoperable HNSCC who underwent induction chemotherapy with low dose nivolumab. Eligible doses of nivolumab were <3mg/kg q2w with chemotherapy backbone of TPX or TP+/- OMCT. The principal outcomes were conversion to radical therapy, ORR, PFS and OS.
Results
We included 111 patients, 78.4% males with median age 48. Primary sites- oral cavity(71.2%), hypopharynx(11.7%), oropharynx(9%) and larynx(8.1%) mainly stage IVA/IVB. TPX/TP was used in 95.4%. Nivolumab 20/40/100 mg all 2/3/4 weeks were the doses and intervals. The harmonized median dose of nivolumab was 0.51 mg/kg q2w (median 3 doses). Response assessment was available for 92 of 111 patients- CR in 7 (6.3%), PR in 65(58.6%), SD in 12(10.8%), PD in 8(7.2%). ORR was 78.2% in those assessed. 25(31.6%) oral cavity tumours became resectable following induction, of whom, 8(32%) had pCR. 60% of oropharyngeal, 69% of hypopharynx and 77.8% of larynx primary site underwent radical RT/CRT after induction. Median PFS is 18.6 months. PFS and OS at 1 year were 64.6% and 82.6%. Median PFS not reached in the cohort with pCR/rCR and 18 months in the group without(p 0.03). No recurrence/death observed thus far in those with pCR. At nivolumab doses <0.6mg/kg, median PFS was significantly lower (13 months vs NR; p 0.04). The retrospective design introduces potential confounders. Grade 3/4 AEs were neutropenia (14.4%), CINV (2.7%), anemia(2.7%), mucositis(1.8%) and febrile neutropenia(1%); Any grade hyponatremia(14%), hypothyroidism(5%).
Conclusions
Low-dose ICI with induction chemotherapy demonstrated promising ORR and conversion to radical therapy. Survival, although immature, appears favourable, especially for patients with pCR/rCR. Doses of nivolumab < 0.6mg/kg may compromise survival. Low-dose (1/6th of standard dose) regimens could enhance ICI access in LMICs due to significantly reduced costs and merit investigation in randomised trials to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board (Ethics committee) of the Christian Medical College Vellor.
Funding
Has not received any fundin.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract